Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment

Michael A. Mohutsky, Annette Romeike, Vince Meador, William M. Lee, John Fowler, Sabine Francke-Carroll

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Hepatic drug metabolizing enzyme (DME) induction complicates the development of new drugs owing to altered efficacy of concomitant treatments, reduction in exposure resulting from autoinduction, and potential generation of toxic metabolites. Risk assessment of DME induction during clinical evaluation is confounded by several uncertainties pertaining to hazard identification and dose response analysis. Hepatic DME induction rarely leads to clinical evidence of altered metabolism and toxicity in the patient, which typically occur only if the DME induction is relatively severe. High drug doses are associated with a greater likelihood of hepatic DME induction and downstream effects; therefore, drugs of low potency requiring higher dosing tend to lead to a greater risk of drug-drug interactions. Vigilance in clinical trials for increased or diminished drug effect and, specifically, pharmacokinetic studies in the presence of other drugs and concomitant diseases are necessary for a drug risk assessment profile. Efforts to remove hepatic DME-inducing drugs from development can be facilitated with current in vitro and in vivo assessments and will improve with the development of newer technologies. A carefully tailored case-by-case approach will lead to the development of efficacious drugs with an acceptable risk/benefit profile available to patients.

Original languageEnglish (US)
Pages (from-to)799-809
Number of pages11
JournalToxicologic Pathology
Volume38
Issue number5
DOIs
StatePublished - Aug 2010

Fingerprint

Enzyme Induction
Risk assessment
Liver
Enzymes
Pharmaceutical Preparations
Drug interactions
Pharmacokinetics
Poisons
Metabolites
Drug Interactions
Metabolism

Keywords

  • drug-metabolizing enzymes
  • enzyme induction
  • hepatic
  • induction
  • metabolism
  • risk assessment

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Toxicology
  • Cell Biology
  • Molecular Biology

Cite this

Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment. / Mohutsky, Michael A.; Romeike, Annette; Meador, Vince; Lee, William M.; Fowler, John; Francke-Carroll, Sabine.

In: Toxicologic Pathology, Vol. 38, No. 5, 08.2010, p. 799-809.

Research output: Contribution to journalArticle

Mohutsky, Michael A. ; Romeike, Annette ; Meador, Vince ; Lee, William M. ; Fowler, John ; Francke-Carroll, Sabine. / Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment. In: Toxicologic Pathology. 2010 ; Vol. 38, No. 5. pp. 799-809.
@article{074148c9f54b4be68c384de745ceda67,
title = "Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment",
abstract = "Hepatic drug metabolizing enzyme (DME) induction complicates the development of new drugs owing to altered efficacy of concomitant treatments, reduction in exposure resulting from autoinduction, and potential generation of toxic metabolites. Risk assessment of DME induction during clinical evaluation is confounded by several uncertainties pertaining to hazard identification and dose response analysis. Hepatic DME induction rarely leads to clinical evidence of altered metabolism and toxicity in the patient, which typically occur only if the DME induction is relatively severe. High drug doses are associated with a greater likelihood of hepatic DME induction and downstream effects; therefore, drugs of low potency requiring higher dosing tend to lead to a greater risk of drug-drug interactions. Vigilance in clinical trials for increased or diminished drug effect and, specifically, pharmacokinetic studies in the presence of other drugs and concomitant diseases are necessary for a drug risk assessment profile. Efforts to remove hepatic DME-inducing drugs from development can be facilitated with current in vitro and in vivo assessments and will improve with the development of newer technologies. A carefully tailored case-by-case approach will lead to the development of efficacious drugs with an acceptable risk/benefit profile available to patients.",
keywords = "drug-metabolizing enzymes, enzyme induction, hepatic, induction, metabolism, risk assessment",
author = "Mohutsky, {Michael A.} and Annette Romeike and Vince Meador and Lee, {William M.} and John Fowler and Sabine Francke-Carroll",
year = "2010",
month = "8",
doi = "10.1177/0192623310375099",
language = "English (US)",
volume = "38",
pages = "799--809",
journal = "Toxicologic Pathology",
issn = "0192-6233",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment

AU - Mohutsky, Michael A.

AU - Romeike, Annette

AU - Meador, Vince

AU - Lee, William M.

AU - Fowler, John

AU - Francke-Carroll, Sabine

PY - 2010/8

Y1 - 2010/8

N2 - Hepatic drug metabolizing enzyme (DME) induction complicates the development of new drugs owing to altered efficacy of concomitant treatments, reduction in exposure resulting from autoinduction, and potential generation of toxic metabolites. Risk assessment of DME induction during clinical evaluation is confounded by several uncertainties pertaining to hazard identification and dose response analysis. Hepatic DME induction rarely leads to clinical evidence of altered metabolism and toxicity in the patient, which typically occur only if the DME induction is relatively severe. High drug doses are associated with a greater likelihood of hepatic DME induction and downstream effects; therefore, drugs of low potency requiring higher dosing tend to lead to a greater risk of drug-drug interactions. Vigilance in clinical trials for increased or diminished drug effect and, specifically, pharmacokinetic studies in the presence of other drugs and concomitant diseases are necessary for a drug risk assessment profile. Efforts to remove hepatic DME-inducing drugs from development can be facilitated with current in vitro and in vivo assessments and will improve with the development of newer technologies. A carefully tailored case-by-case approach will lead to the development of efficacious drugs with an acceptable risk/benefit profile available to patients.

AB - Hepatic drug metabolizing enzyme (DME) induction complicates the development of new drugs owing to altered efficacy of concomitant treatments, reduction in exposure resulting from autoinduction, and potential generation of toxic metabolites. Risk assessment of DME induction during clinical evaluation is confounded by several uncertainties pertaining to hazard identification and dose response analysis. Hepatic DME induction rarely leads to clinical evidence of altered metabolism and toxicity in the patient, which typically occur only if the DME induction is relatively severe. High drug doses are associated with a greater likelihood of hepatic DME induction and downstream effects; therefore, drugs of low potency requiring higher dosing tend to lead to a greater risk of drug-drug interactions. Vigilance in clinical trials for increased or diminished drug effect and, specifically, pharmacokinetic studies in the presence of other drugs and concomitant diseases are necessary for a drug risk assessment profile. Efforts to remove hepatic DME-inducing drugs from development can be facilitated with current in vitro and in vivo assessments and will improve with the development of newer technologies. A carefully tailored case-by-case approach will lead to the development of efficacious drugs with an acceptable risk/benefit profile available to patients.

KW - drug-metabolizing enzymes

KW - enzyme induction

KW - hepatic

KW - induction

KW - metabolism

KW - risk assessment

UR - http://www.scopus.com/inward/record.url?scp=77958524342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958524342&partnerID=8YFLogxK

U2 - 10.1177/0192623310375099

DO - 10.1177/0192623310375099

M3 - Article

C2 - 20616377

AN - SCOPUS:77958524342

VL - 38

SP - 799

EP - 809

JO - Toxicologic Pathology

JF - Toxicologic Pathology

SN - 0192-6233

IS - 5

ER -